MedPath

NATIONAL INSTITUTES OF HEALTH

NATIONAL INSTITUTES OF HEALTH logo
πŸ‡ΊπŸ‡ΈUnited States
Ownership
Subsidiary, Private
Established
1948-01-01
Employees
1K
Market Cap
-
Website
http://www.nidcr.nih.gov

Vorinostat, Paclitaxel, and Carboplatin in Treating Patients With Advanced or Refractory Solid Tumors

Phase 1
Completed
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
Other: laboratory biomarker analysis
Other: pharmacological study
First Posted Date
2006-02-07
Last Posted Date
2013-02-07
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
30
Registration Number
NCT00287937
Locations
πŸ‡ΊπŸ‡Έ

University of Pittsburgh, Pittsburgh, Pennsylvania, United States

Uric Acid in Essential Hypertension in Children

Phase 2
Completed
Conditions
Essential Hypertension
Interventions
Drug: Placebo
First Posted Date
2006-02-07
Last Posted Date
2017-09-14
Lead Sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Target Recruit Count
30
Registration Number
NCT00288184
Locations
πŸ‡ΊπŸ‡Έ

Texas Children's Hospital, Houston, Texas, United States

The Diabetes TeleCare Study

Not Applicable
Completed
Conditions
Diabetes Mellitus, Type 2
Interventions
Behavioral: Intervention
Behavioral: Usual Care
First Posted Date
2006-02-07
Last Posted Date
2018-03-02
Lead Sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Target Recruit Count
165
Registration Number
NCT00288132
Locations
πŸ‡ΊπŸ‡Έ

CareSouth Bennettsville, Bennettsville, South Carolina, United States

BAY 43-9006 (Sorafenib) to Treat Patients With Kaposi's Sarcoma

Phase 1
Terminated
Conditions
Kaposi's Sarcoma
HHV-8
KSHV
Interventions
First Posted Date
2006-02-06
Last Posted Date
2019-12-12
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
10
Registration Number
NCT00287495
Locations
πŸ‡ΊπŸ‡Έ

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Dietary Variety Versus Dietary Fat Effects in Energy Intake

Phase 1
Completed
Conditions
Healthy
First Posted Date
2006-02-02
Last Posted Date
2010-03-18
Lead Sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Target Recruit Count
64
Registration Number
NCT00285571
Locations
πŸ‡ΊπŸ‡Έ

Bastyr University, Kenmore, Washington, United States

Peer-enhanced Intervention to Support Teen Weight Loss

Not Applicable
Completed
Conditions
Obesity
Interventions
Behavioral: CBT with supervised aerobic exercise
Behavioral: CBT with peer-enhanced activities
First Posted Date
2006-02-02
Last Posted Date
2017-10-06
Lead Sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Target Recruit Count
118
Registration Number
NCT00285558
Locations
πŸ‡ΊπŸ‡Έ

Bradley Hasbro Children's Research Center, Providence, Rhode Island, United States

HALT Progression of Polycystic Kidney Disease Study A

Phase 3
Completed
Conditions
Kidney, Polycystic
Interventions
Drug: Placebo
Other: Low Blood Pressure Control
Other: Standard Blood Pressure Control
First Posted Date
2006-01-30
Last Posted Date
2020-04-21
Lead Sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Target Recruit Count
558
Registration Number
NCT00283686
Locations
πŸ‡ΊπŸ‡Έ

University of Colorado Health Sciences Center, Aurora, Colorado, United States

πŸ‡ΊπŸ‡Έ

Tufts University-New England Medical Center, Boston, Massachusetts, United States

πŸ‡ΊπŸ‡Έ

Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

and more 4 locations

Body Weight Regulation in Patients With Narcolepsy

Completed
Conditions
Narcolepsy
First Posted Date
2006-01-30
Last Posted Date
2017-10-06
Lead Sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Target Recruit Count
30
Registration Number
NCT00283894
Locations
πŸ‡ΊπŸ‡Έ

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Combination Chemotherapy in Treating Young Patients With Advanced Solid Tumors

Phase 1
Completed
Conditions
Childhood Central Nervous System Choriocarcinoma
Childhood Central Nervous System Embryonal Tumor
Childhood Central Nervous System Germ Cell Tumor
Childhood Central Nervous System Germinoma
Childhood Central Nervous System Mixed Germ Cell Tumor
Childhood Central Nervous System Teratoma
Childhood Central Nervous System Yolk Sac Tumor
Recurrent Childhood Brain Stem Glioma
Recurrent Childhood Central Nervous System Embryonal Tumor
Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
Other: pharmacological study
Procedure: positron emission tomography
Procedure: computed tomography
First Posted Date
2006-01-25
Last Posted Date
2013-05-03
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
42
Registration Number
NCT00281944
Locations
πŸ‡ΊπŸ‡Έ

Memorial Sloan Kettering Cancer Center, New York, New York, United States

Sorafenib With Either Temsirolimus or Tipifarnib in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed By Surgery

Phase 2
Completed
Conditions
Stage IV Melanoma
Recurrent Melanoma
Interventions
First Posted Date
2006-01-25
Last Posted Date
2014-05-20
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
109
Registration Number
NCT00281957
Locations
πŸ‡ΊπŸ‡Έ

Contra Costa Regional Medical Center, Martinez, California, United States

πŸ‡ΊπŸ‡Έ

El Camino Hospital, Mountain View, California, United States

πŸ‡ΊπŸ‡Έ

Great Falls Clinic, Great Falls, Montana, United States

and more 170 locations
Β© Copyright 2025. All Rights Reserved by MedPath